Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction

Psychopharmacology

Volumn 161, Issue 1, 2002, Pages 1-16

  Tzschentke, Thomas M ^a  

^a GRÜNENTHAL GMBH   (Germany)

Author keywords

Conditioned place preference; Dependence; Drug discrimination; Fentanyl; Intracranial self stimulation; Intravenous self administration; Morphine; Partial agonist reward; Reinforcement; Sensitization; Tolerance

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 5,9 DIETHYL 2 (3 FURYLMETHYL) 2' HYDROXY 6,7 BENZOMORPHAN; ALFENTANIL; BREMAZOCINE; BUPRENORPHINE; BUTORPHANOL; COCAINE; CODEINE; DEZOCINE; DIAMORPHINE; ETHYLKETAZOCINE; ETORPHINE; FENTANYL; LEVORPHANOL; METHADONE; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALBUPHINE; NALOXONE; NALTREXONE; PENTAZOCINE; PETHIDINE;

ANALGESIA; BEHAVIOR; BRAIN DEPTH STIMULATION; COCAINE DEPENDENCE; CONDITIONING; DETOXIFICATION; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG DOSAGE FORM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG SENSITIZATION; DRUG WITHDRAWAL; HEROIN DEPENDENCE; HUMAN; MAINTENANCE THERAPY; NONHUMAN; PAIN; PLACE PREFERENCE; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; REWARD; SELF STIMULATION; SIDE EFFECT; SLOW RELEASE FORMULATION; SUBSTANCE ABUSE; TRANSDERMAL PATCH;

ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; CONDITIONING (PSYCHOLOGY); DISCRIMINATION LEARNING; HUMANS; MOTOR ACTIVITY; NALOXONE; REWARD; SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS;

EID: 0036233866     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1003-8     Document Type: Review

References (211)

1. Time-dose relationships for locomotor activity effects of morphine after acute or repeated treatment
2. Conditioned place preference: What does it add to our preclinical understanding of drug reward?
3. Effects of buprenorphine on motility in chronically morphine treated rats
4. Effects of buprenorphine on motility in morphine post-dependent rats
5. Sensitization to the morphine-like discriminative stimulus effects of buprenorphine in rats
6. Abuse liability of buprenorphine - A study among experienced drug users
7. Buprenorphine treatment of opioid dependence: A review
8. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts
9. Buprenorphine: Dose-related blockade of opioid challenge effects in opioid-dependent humans
10. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor
11. Clinical actions of fentanyl and buprenorphine
12. Discriminative stimulus effects of l-alpha-acetylmethadol (LAAM), buprenorphine and methadone in morphine-treated rhesus monkeys
13. Methoclocinnamox: Time course of changes in alfentanil-reinforced responding in rhesus monkeys
14. Behavioral and neurochemical interactions between cocaine and buprenorphine: Implications for the pharmacotherapy of cocaine abuse
15. Antinociceptive actions of morphine and buprenorphine given intrathecally in the conscious rat
16. Conditioned place preference as a measure of drug reward
17. Effects of buprenorphine on self-administration of cocaine and a nondrug reinforcer in rats
18. Cocaine receptor: Biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter
19. Buprenorphine's effects on self-administration of smoked cocaine and orally delivered phencyclidine, ethanol and saccharin in rhesus monkeys
20. Phencyclidine (PCP) self-administration and withdrawal in rhesus monkeys: Effects of buprenorphine and dizocilpine (MK-801) pretreatment
21. Opioid receptor-coupled second messenger systems
22. Buprenorpine abuse: Report from India
23. Cellular site of opiate dependence
24. Discriminative stimulus properties of narcotic analgesic drugs
25. Drug discrimination: No evidence for tolerance to opiates
26. Drug discrimination in neurobiology
27. Discriminative stimulus properties of fentanyl and morphine: Tolerance and dependence
28. Effects of concurrent saccharin availability and buprenorphine treatment on demand for smoked cocaine base in rhesus monkeys
29. Combined effects of buprenorphine and a nondrug alternative reinforcer on IV cocaine self-administration in rats maintained under FR schedules
30. The effect of acute doses of buprenorphine on concentrations of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) in the rat fore-brain
31. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent
32. The animal pharmacology of buprenorphine, an oripavine analgesic agent
33. Effect of gonadectomy on discriminative stimulus effects of morphine in female versus male rats
34. The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity
35. Buprenorphine and cocaine effects on social behavior of monkeys
36. A comparison of the neurochemical effects of buprenorphine with those of morphine and haloperidol in rats
37. Neurobiology of opiate abuse
38. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions
39. Buprenorphine: Demonstration of physical dependence liability
40. Behavioral effects of buprenorphine and diprenorphine under a multiple schedule of food presentation in squirrel monkeys
41. Discriminative stimulus properties of cocaine, alone and in combination with buprenorphine, morphine and naltrexone
42. Heroin and cocaine intravenous self-administration in rats: Mediation by separate neural systems
43. Effects of buprenorphine on the self-administration of cocaine by humans
44. The interaction of buprenorphine with cocaine-morphine combinations
45. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans
46. Opiate agonist-antagonist interactions: Application of a three-key drug discrimination procedure
47. Discriminative stimulus effects of opioid agonists in morphine-dependent pigeons
48. Discriminative stimulus effects of reversible and irreversible opiate agonists: Morphine, oxymorphazone and buprenorphine
49. Abrupt withdrawal of buprenorphine following chronic administration
50. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal
51. Effects of morphine, naloxone, buprenorphine, butorphanol, haloperidol and imipramine on morphine withdrawal signs in cynomolgus monkeys
52. Sensitivity to the narcotic cue in non-dependent, morphine-dependent and post-dependent rats
53. Motivational properties of buprenorphine as assessed by place and taste conditioning in rats
54. The suppression of deprivation and antagonist-induced withdrawal in morphine-dependent rhesus monkeys
55. Buprenorphine and morphine produce equivalent increases in extracellular single unit activity of dopamine neurons in the ventral tegmental area in vivo
56. Buprenorphine fully suppresses spontaneous activity in the locus coeruleus
57. Morphine-induced activation of A10 dopamine neurons in the rat
58. The interaction of buprenorphine with the opiate receptor: Lipophilicity as a determining factor in drug-receptor kinetics
59. Buprenorphine and temazepam-abuse
60. Buprenorphine: A case report
61. Pharmacological evaluation of narcotic antagonist delivery systems in rhesus monkeys
62. Buprenorphine: A review of its pharmacological properties and therapeutic efficacy
63. Cocaine, d-amphetamine, and pentobarbital effects on responding maintained by food or cocaine in rhesus monkeys
64. A comparison of the stimulus effects of codeine in rhesus monkeys under the contingencies of a two lever discrimination task and a cross self-administration paradigm: Tests of generalization to pentazocine, buprenorphine, tilidine, and different doses of codeine
65. Discriminative stimulus effects of buprenorphine in the rat
66. Preexposure sensitizes rats to the rewarding effects of cocaine
67. Analgesic effectiveness of the narcotic agonist-antagonists
68. The reinforcing properties of the mixed agonist-antagonist buprenorphine as assessed by brain-stimulation reward
69. The role of withdrawal in heroin addiction: Enhances reward or promotes avoidance?
70. Human pharmacology and abuse potential of the analgesic buprenorphine
71. Progress report of the NIDA Addiction Research Center
72. Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction
73. A controlled trial of buprenorphine treatment for opioid dependence
74. Opioids excite dopamine neurons by hyperpolarization of local interneurons
75. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose discrimination procedure
76. Agonist and antagonist actions of buprenorphine on three types of opioid receptor in isolated preparations
77. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity
78. Modulation of the discriminative stimulus effect of cocaine by buprenorphine
79. Buprenorphine potentiates behavioral effects of cocaine in squirrel monkeys
80. The effects of naloxone on behavior maintained by cocaine and heroin injections in rhesus monkeys
81. Neuroanatomical substrates of drug self-administration
82. Opponent process theory of motivation: Neurobiological evidence from studies of opiate dependence
83. Role of opioid antagonists in treating intravenous cocaine abuse
84. Treatment of cocaine abuse with buprenorphine
85. Opioid antagonist challenges in buprenorphine maintained patients
86. Cocaine conditioned place preference is attenuated by chronic buprenorphine treatment
87. Interactions of opioids with caffeine: Evaluation by ambulatory activity in mice
88. Central beta-adrenergic receptor-adenylate cyclase system and formation of morphine withdrawal syndrome
89. HS-599: A novel long acting opioid analgesic does not induce place-preference in rats
90. Opioid agonist and antagonist behavioral effects of buprenorphine
91. Buprenorphine has potent kappa opioid receptor antagonist activity
92. Repeated exposures intensify rather than diminish the rewarding effects of amphetamine, morphine, and cocaine
93. A protocol to switch high-dose, methadone-maintained subjects to buprenorphine
94. Buprenorphine
95. Respiratory effects of opioid full and partial agonists in rhesus monkeys
96. Buprenorphine self-administration by the baboon: Comparison with other opioids
97. Comparison of opioid self-injection and disruption of schedule-controlled performance in the baboon
98. Differential tolerance development to buprenorphine-, diprenorphine-, and heroin-induced disruption of food maintained responding in macaque monkeys
99. Buprenorphine-induced alterations of cocaine's reinforcing effects in rhesus monkey: A dose-response analysis
100. Drug addiction as a physical disease: The role of physical dependence and other chronic drug-induced neurophysiological changes in compulsive drug self-administration
101. The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties
102. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog
103. Buprenorphine suppresses heroin use by heroin addicts
104. Behavioral pharmacology of buprenorphine
105. The effects of buprenorphine on self-administration of cocaine and heroin "speedball" combinations and heroin alone by rhesus monkeys
106. Buprenorphine self-administration by rhesus monkeys
107. Buprenorphine effects on human heroin self-administration: An operant analysis
108. Comparison of buprenorphine and methadone effects on opiate self-administration in primates
109. Buprenorphine effects on food-maintained responding in macaque monkeys
110. Progressive ratio performance maintained by buprenorphine, heroin and methadone in macaque monkeys
111. Buprenorphine suppresses cocaine self-administration by rhesus monkeys
112. Buprenorphine and naltrexone effects on cocaine self-administration by rhesus monkeys
113. The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys
114. Effects of intermittent buprenorphine administration on cocaine self-administration by rhesus monkeys
115. Naltrexone-buprenorphine interactions: Effects on cocaine self-administration
116. Buprenorphine attenuates the effects of cocaine on adrenocorticotropin (ACTH) secretion and mood states in man
117. Tolerance to morphine-produced discriminative stimuli and analgesia
118. The μ opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the μ opioid receptor
119. Sensitivity to the discriminative stimulus and antinociceptive effects of μ opioids: Role of strain of rat, stimulus intensity, and intrinsic efficacy at the μ opioid receptor
120. Kappa antagonist properties of buprenorphine in the shock titration procedure
121. Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats
122. Interactions between mu and kappa opioid agonists in the rat drug discrimination procedure
123. Interactions between the discriminative stimulus effects of mu and kappa opioid agonists in the squirrel monkey
124. Effects of kappa opioids on cocaine self-administration by rhesus monkeys
125. Molecular and cellular mechanisms of opiate action: Studies in the rat locus coeruleus
126. Dopaminergic neurons: Effect of acute and chronic morphine administration on single cell activity and transmitter metabolism
127. Bupre-norphine abuse among opiate addicts
128. Sensitization and tolerance to the discriminative stimulus effects of mu-opioid agonists
129. Simple methodology of assessment of analgesics' addictive potential in mice
130. Neuroanatomical bases of intracranial self-stimulation: Untangling the Gordian knot
131. Kappa agonist and antagonist properties of mixed action opioids in a pigeon drug discrimination procedure
132. Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: Cross-substitution by mu and delta opioid agonists
133. Discriminative stimulus effects of opioids in pigeons trained to discriminate fentanyl, bremazocine and water: Evidence of pharmacological selectivity
134. Discriminative stimulus effects of mu and kappa opioids in the pigeon: Analysis of the effects of full and partial mu and kappa agonists
135. Agonist and antagonist effects of mixed action opioids in the pigeon drug discrimination procedure: Influence of training dose, intrinsic efficacy and interanimal differences
136. Subjective and physiologic effects of intravenous buprenorphine in humans
137. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants
138. Buprenorphine as a stimulus in drug discrimination learning: An assessment of mu and kappa receptor activity
139. Abuse liability studies of opioid agonist-antagonists in humans
140. Drug discrimination assessment of agonist-antagonists in humans: A three-choice saline-hydromorphone-butorphanol procedure
141. Drug discrimination in human postaddicts: Agonist-antagonist opioids
142. Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination
143. A case of buprenorphine abuse
144. The influence of drug-receptor kinetics on the pharmacological and pharmacokinetic profiles of buprenorphine
145. Biphasic dose-response to buprenorphine in the rat tail-flick assay: Effect of naloxone pretreatment
146. Buprenorphine is an antagonist at the kappa opioid receptor
147. The effects of chronic morphine on the generalization of buprenorphine stimulus control: An assessment of kappa antagonist activity
148. The neural basis of drug craving: An incentive-sensitization theory of addiction
149. Buprenorphine: Duration of blockade of effects of intramuscular hydromorphone
150. In vivo receptor binding of opioid drugs at the mu site
151. Cyclic nucleotides and the central effects of opiates: An overview of current research
152. Involvement of mu and kappa receptors in the analgesic effect of buprenorphine
153. Dissociation of buprenorphine-induced locomotor sensitization and conditioned place preference in rats
154. Buprenorphine: Differential interaction with opiate receptor subtypes in vivo
155. Assessment and management of opioid withdrawal symptoms in buprenorphine-dependent subjects
156. Consumption of buprenorphine and other drugs among heroin addicts under ambulatoty treatment: Results from cross-sectional studies in 1988 and 1990
157. Environmental modification of tolerance to morphine discriminative stimulus properties in rats
158. Morphine-like stimulus effects in the monkeys: Opioids with antagonist properties
159. Buprenorphine: Dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans
160. The guinea-pig ileum as an in vitro model to analyze dependence liability of narcotic drugs
161. Morphine-like discriminative stimulus effects of buprenorphine and demethoxy-buprenorphine in rats: Quantitative antagonism by naloxone
162. Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance
163. Sensitization to the conditioned rewarding effects of cocaine: Pharmacological and temporal characteristics
164. Sensitization to the conditioned rewarding effects of morphine: Pharmacology and temporal characteristics
165. κ-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine
166. Cases of buprenorphine abuse in India
167. Modulation of the discriminative stimulus effects of cocaine by mu and kappa opioids
168. Pharmacological basis of intracranial self-stimulation reward
169. Tolerance and sensitization to the behavioral effects of drugs
170. Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987
171. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers
172. Comparison of buprenorphine and methadone in the treatment of opioid dependence
173. Discrete-trial control of cocaine self-injection behavior in squirrel monkeys: Effects of morphine, naltrexone and chlorpromazine
174. The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference
175. Buprenorphine effects on morphine- and cocaine-induced subjective responses by drug-dependent men
176. Buprenorphine prevents and reverses the expression of chronic etophine-induced sensitization of adenylyl cyclase in SK-N-SH human neuroblastoma cells
177. Are NMDA receptors involved in opiate-induced neural and behavioral plasticity? A review of preclinical studies
178. Measuring reward with the conditioned place preference paradigm: A comprehensive review of drug effects, recent progress and new issues
179. Buprenorphine in conditioned place preference in the rat
180. Does the noncompetitive NMDA receptor antagonist dizocilpine (MK-801) really block behavioural sensitization associated with repeated drug administration?
181. Blockade of behavioral sensitization by MK-801: Fact or artifact? A review of preclinical data
182. Discriminative stimulus effects of naltrexone in narcotic-naive and morphine-treated pigeons
183. Place conditioning: A simple and effective method for assessing the motivational properties of drugs
184. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: A critical review of preclinical studies
185. The involvement of endorphines in drug self-administration
186. Opioids, reward and addiction: An encounter of biology, psychology, and medicine
187. Buprenorphine: Characteristics of binding sites in the rat central nervous system
188. Discriminative-stimulus effects of the low efficacy mu agonist nalbuphine
189. In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats
190. Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure
191. Clinical pharmacology of buprenorphine: Ceiling effects at high doses
192. Acute administration of buprenorphine in humans: Partial agonist and blockade effects
193. Dynamics of drug dependence. Implications of a conditioning theory for research and treatment
194. Effects of buprenorphine on behavior maintained by heroin and alfentanil in rhesus mokeys
195. Effects of buprenorphine and other opioid agonists and antagonists on alfentanil-and cocaine-reinforced responding in rhesus monkeys
196. Addictive drugs and brain stimulation reward
197. Neurobiology of addiction
198. A psychomotor stimulant theory of addiction
199. Psychomotor-stimulant sensitization: A unitary phenomenon?
200. Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered gene assay
201. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants
202. Endogenous opioids and cyclic AMP
203. Narcotic-reinforced responding: A rapid screening procedure
204. Substitution and primary dependence studies in animals
205. Multiple opiate receptors: Differential binding of mu, kappa and delta agonists
206. Behavioral pharmacology of buprenorphine: Issues relevant to its potential in treating abuse
207. Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids
208. Tolerance to morphine-like stimulus effects of mu opioid agonists
209. Onset of tolerance to discriminative stimulus effects of morphine
210. Discriminative stimulus effects of morphine: Effects of training dose on agonist and antagonist effects of mu opioids